Akari Therapeutics (STU:CLA1) ROCE %: -219.62% (As of Mar. 2026)


STU:CLA1 Akari Therapeutics PLC STU:CLA1
32 GF Score
Price €134.40
View Full Analysis

What is Akari Therapeutics ROCE %?

Akari Therapeutics STU:CLA1 32 ROCE % is -219.62% as of Mar. 2026. GuruFocus rates STU:CLA1 with a GF Score™ of 32/100.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Akari Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2026 was -219.62%.

Akari Therapeutics  (STU:CLA1) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Akari Therapeutics ROCE % Related Terms

Akari Therapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for Akari Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akari Therapeutics ROCE % Chart

Akari Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -241.24 -659.85 -1,240.14 -128.46 -49.71

Akari Therapeutics Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -47.32 -22.43 -91.84 -55.02 -219.62
STU:CLA1
32GF Score
Akari Therapeutics PLC STU:CLA1
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Akari Therapeutics ROCE % Calculation

Akari Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-14.819/( ( (48.287 - 19.014) + (40.9 - 10.548) )/ 2 )
=-14.819/( (29.273+30.352)/ 2 )
=-14.819/29.8125
=-49.71 %

Akari Therapeutics's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-52.776/( ( (40.9 - 10.548) + (29.314 - 11.604) )/ 2 )
=-52.776/( ( 30.352 + 17.71 )/ 2 )
=-52.776/24.031
=-219.62 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -219.62% mean?
Akari Therapeutics (STU:CLA1) has a ROCE % of -219.62% as of Mar. 2026.
Is Akari Therapeutics' ROCE % too high?
Akari Therapeutics' current ROCE % is -219.62%. Overall, Akari Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Akari Therapeutics' ROCE % compare to MBRX and JAGX?
Akari Therapeutics' ROCE % of -219.62% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Akari Therapeutics's current ROCE % is -219.62%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akari Therapeutics stock overvalued right now?
Akari Therapeutics (STU:CLA1) has a current ROCE % of -219.62%. The current ROCE % is -219.62%. Akari Therapeutics' overall GF Score™ is 32/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Akari Therapeutics (STU:CLA1), the current ROCE % is -219.62% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Akari Therapeutics Business Description

Other Exchanges AKTX:USA
Address 401 East Jackson Street, Suite 3300, Tampa, FL, USA, 33602
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.
32GF Score

Get the complete analysis for STU:CLA1

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€134.40
Price